Novo Nordisk recommends asking these questions to an insurance company that does not cover Wegovy: Are there any other options to get Wegovy covered by insurance
Semaglutide (SUSTAIN and PIONEER) Reduces Cardiovascular Events in Type 2 Diabetes Across Varying Cardiovascular Risk
However, much like all medication, they might not be suitable for everyone
Considerations & Potential Risks While the benefits are promising, GLP-1RA users have also reported some increased risks, including: Gastrointestinal issues (nausea, heartburn, abdominal pain, and gastroparesis)
The remainder of the Agreement will remain in full effect
Stimulation of the GLP-1 receptors was additionally reported to provide with several advantages including the weight loss, enhanced glycemic control, improved cardiovascular and liver functions